The line between a medical procedure and a consumer product has been moving for years. Blood pressure cuffs, glucose monitors and heart rhythm sensors now sit in ordinary households. Skincare is following a similar path, and it raises familiar questions about evidence, regulation and data.
Few categories show this more clearly than at-home micro infusion. Devices sold as the best micro infusion system for home use now reach hundreds of thousands of buyers, and the way their results are measured looks very different from what a hospital purchasing committee would ask for.
From clinic to consumer
Microneedling began as an in-office procedure, performed by clinicians with longer needles and supported by a body of clinical research, much of it on acne scars, though many of the studies are small.
Consumer devices took the idea in a different direction. They use much shorter needles, are designed for self-use and focus on what manufacturers call micro infusion: helping a serum absorb better than it would from the surface alone. They are cosmetic products, not procedures.
Seranova, an at-home skincare company, illustrates how the category has developed. Its system pairs a stamping device with sterile, single-use needle heads and a peptide and hyaluronic acid serum. The company reports more than one million units sold and more than 500,000 customers.
A regulatory gray zone
In the United States, the regulatory status of needle devices depends heavily on how a device is designed and marketed. Products intended to treat scars or wrinkles can fall under the Food and Drug Administration’s device oversight. Products positioned as cosmetic, focused on product absorption or appearance, often do not go through the same review.
That distinction matters for how claims are made. Seranova, like many companies in the space, states that its products have not been evaluated by the F.D.A. and are not intended to diagnose, treat, cure or prevent any disease. Its claims are framed around appearance: skin that looks firmer, smoother or more even.
For health technology observers, this is a familiar pattern. Consumer products can reach the market faster and at lower cost than regulated medical devices, and the type of evidence behind them is often different.
How companies measure results
The data that consumer skincare companies publish tends to fall into three categories.
The first is safety and tolerance testing. Seranova cites dermatological testing in two studies of 30 subjects each to support skin compatibility. Studies of this kind are standard in the industry and are designed to detect irritation.
The second is clinical testing over a longer period. Seranova cites a 12-week study of 29 participants, conducted by EpiDermLab, an independent laboratory in Kraków, Poland. The company reports that 93 percent of participants had visibly firmer-looking skin, 72 percent a reduced appearance of wrinkles and 66 percent visibly smoother skin, with tolerance rated excellent and no adverse events. The company itself notes that the sample is small and that the study was not placebo-controlled, which is typical of cosmetic testing. Full reports, it says, are available on request.
The third is customer-reported outcomes. In a January 2026 survey of 281 Seranova customers who had purchased more than once, 80 percent said their skin appeared firmer, 78 percent said it looked younger and 87 percent said no recovery time was needed. The company discloses that these results are self-reported and not independently verified. Results vary.
That level of disclosure is worth noting. It is also a reminder of what each type of data can and cannot show. Repeat buyers are a self-selected group, and perceived improvement is a different measure from an instrument reading in a study.
An opportunity for better evidence
The challenge is not unique to skincare. Across consumer health, companies hold large amounts of user data that are rarely analyzed in ways that would satisfy a clinical reviewer. Standardized photography, validated outcome scales and independent analysis could turn customer feedback into something closer to real-world evidence.
Several features of products like Seranova’s already make that more feasible. Single-use heads and fixed session intervals, one session every two weeks, create a consistent protocol. A 90-day guarantee that asks customers to document progress with monthly photos generates structured before-and-after images.
What buyers should weigh
For now, consumers are left to evaluate claims on their own. Practical signals include sterile, single-use components, transparent ingredient lists, clear contraindications, published study information and refund policies that let users test results without a large financial risk.
Seranova points to its sterile heads, its 90-day guarantee and industry awards from beauty publications. How the category as a whole develops will depend on the next step: data that is collected and analyzed with the same rigor that health technology increasingly expects elsewhere.
The devices have already moved into the home. The evidence around them is still growing.

